153 related articles for article (PubMed ID: 22619125)
21. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.
Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J
Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447
[TBL] [Abstract][Full Text] [Related]
22. Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis.
Lee JH; Choi JW; Kim YS
Br J Dermatol; 2011 Apr; 164(4):776-84. PubMed ID: 21166657
[TBL] [Abstract][Full Text] [Related]
23. Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy.
Casula M; Colombino M; Satta MP; Cossu A; Lissia A; Budroni M; Simeone E; Calemma R; Loddo C; Caracò C; Mozzillo N; Daponte A; Comella G; Canzanella S; Guida M; Castello G; Ascierto PA; Palmieri G;
Eur J Cancer; 2007 Jan; 43(1):137-43. PubMed ID: 17055252
[TBL] [Abstract][Full Text] [Related]
24. Toward a molecular classification of melanoma.
Fecher LA; Cummings SD; Keefe MJ; Alani RM
J Clin Oncol; 2007 Apr; 25(12):1606-20. PubMed ID: 17443002
[TBL] [Abstract][Full Text] [Related]
25. Are all melanomas the same? Spitzoid melanoma is a distinct subtype of melanoma.
Lee DA; Cohen JA; Twaddell WS; Palacios G; Gill M; Levit E; Halperin AJ; Mones J; Busam KJ; Silvers DN; Celebi JT
Cancer; 2006 Feb; 106(4):907-13. PubMed ID: 16421887
[TBL] [Abstract][Full Text] [Related]
26. Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?
Passeron T; Lacour JP; Allegra M; Ségalen C; Deville A; Thyss A; Giacchero D; Ortonne JP; Bertolotto C; Ballotti R; Bahadoran P
Exp Dermatol; 2011 Dec; 20(12):1030-2. PubMed ID: 22092579
[TBL] [Abstract][Full Text] [Related]
27. Pathologist initiated reflex BRAF mutation testing in metastatic melanoma: experience at a specialist melanoma treatment centre.
Potter AJ; Colebatch AJ; Rawson RV; Ferguson PM; Cooper WA; Gupta R; O'Toole S; Saw RPM; Ch'ng S; Menzies AM; Long GV; Scolyer RA
Pathology; 2022 Aug; 54(5):526-532. PubMed ID: 35249747
[TBL] [Abstract][Full Text] [Related]
28. BRAF, NRAS and HRAS mutations in spitzoid tumours and their possible pathogenetic significance.
Da Forno PD; Pringle JH; Fletcher A; Bamford M; Su L; Potter L; Saldanha G
Br J Dermatol; 2009 Aug; 161(2):364-72. PubMed ID: 19438459
[TBL] [Abstract][Full Text] [Related]
29. Method of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasms.
Miller CJ; Cheung M; Sharma A; Clarke L; Helm K; Mauger D; Robertson GP
J Invest Dermatol; 2004 Nov; 123(5):990-2. PubMed ID: 15482489
[No Abstract] [Full Text] [Related]
30. V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours.
Agaimy A; Terracciano LM; Dirnhofer S; Tornillo L; Foerster A; Hartmann A; Bihl MP
J Clin Pathol; 2009 Jul; 62(7):613-6. PubMed ID: 19561230
[TBL] [Abstract][Full Text] [Related]
31. Primary dermal melanoma: A case report and molecular characterization.
Hida Y; Kubo Y; Miyajima O; Arase S
J Dermatol; 2009 Jun; 36(6):346-52. PubMed ID: 19500183
[TBL] [Abstract][Full Text] [Related]
32. Molecular characterization of human cutaneous melanoma-derived cell lines.
Ogbah Z; Puig-Butille JA; Simonetta F; Badenas C; Cervera R; Milá J; Benitez D; Malvehy J; Vilella R; Puig S
Anticancer Res; 2012 Apr; 32(4):1245-51. PubMed ID: 22493355
[TBL] [Abstract][Full Text] [Related]
33. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G
J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978
[TBL] [Abstract][Full Text] [Related]
34. Absence of BRAF gene mutations differentiates spitz nevi from malignant melanoma.
Mihic-Probst D; Perren A; Schmid S; Saremaslani P; Komminoth P; Heitz PU
Anticancer Res; 2004; 24(4):2415-8. PubMed ID: 15330192
[TBL] [Abstract][Full Text] [Related]
35. Malignant neurocristic hamartoma: a tumor distinct from conventional melanoma and malignant blue nevus.
Linskey KR; Dias-Santagata D; Nazarian RM; Le LP; Lam Q; Bellucci KS; Robinson-Bostom L; Mihm MC; Hoang MP
Am J Surg Pathol; 2011 Oct; 35(10):1570-7. PubMed ID: 21934481
[TBL] [Abstract][Full Text] [Related]
36. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
Ogawa K; Sun C; Horii A
Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathology of malignant melanoma: changing the clinical practice paradigm toward a personalized approach.
Bradish JR; Cheng L
Hum Pathol; 2014 Jul; 45(7):1315-26. PubMed ID: 24856851
[TBL] [Abstract][Full Text] [Related]
38. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.
Saldanha G; Potter L; Daforno P; Pringle JH
Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595
[TBL] [Abstract][Full Text] [Related]
39. [Therapeutic approaches in Melanoma - a paradigm for personalized medicine].
Dummer R; Goldinger S; Rinderknecht J; Eggmann N; Felderer L; Braun R; French LE
Praxis (Bern 1994); 2012 Jul; 101(15):955-9. PubMed ID: 22811327
[TBL] [Abstract][Full Text] [Related]
40. External quality assessment of BRAF molecular analysis in melanoma.
Deans ZC; Wallace A; O'Sullivan B; Purvis A; Camus S; Fairley JA; Gonzalez D
J Clin Pathol; 2014 Feb; 67(2):120-4. PubMed ID: 24098023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]